On July 28, Bristol-Myers Squibb
- Excluding special items, earnings per share were $0.47, easily besting Street estimates. That's a big improvement over last year.
- Net income was aided by $294 million in tax benefits, giving Bristol-Myers an effective tax rate of -1.9% during the quarter.
(Figures in millions, except per-share data)
Income Statement Highlights (What's this?)
|
Avg. Est. |
Q2 2005 |
Q2 2004 |
% Change |
|
|---|---|---|---|---|
|
Sales |
$4,800 |
$4,889 |
$4,819 |
+1.5% |
|
Net Profit |
-- |
$1,004 |
$527 |
+90.5% |
|
EPS |
$0.36 |
$0.50 |
$0.27 |
+85.2% |
Margin Checkup (What's this?)
|
Q2 2005 |
Q2 2004 |
Change |
|
|---|---|---|---|
|
Gross Margin |
69.67% |
68.87% |
+0.79% |
|
Op. Margin |
23.11% |
15.96% |
+7.16% |
|
Net Margin |
20.54% |
10.94% |
+9.60% |
Balance Sheet Highlights (What's this?)
No balance sheet data provided. (Boo!)
Cash Flow Highlights (What's this?)
No cash flow statement provided. (Hiss!)
Related Companies:
-
ImClone Systems
(NASDAQ:IMCL) -
Merck
(NYSE:MRK) -
Novartis
(NYSE:NVS) -
Pfizer
(NYSE:PFE) -
Sanofi-Aventis
(NYSE:SNY) -
Schering-Plough
(NYSE:SGP)
Related Foolishness:
- Do you have the patience to invest in Bristol-Myers Squibb?
- It could be a good bet. The Feds let the company off cheap.
- At least Bristol-Myers got some headache relief in January.
You don't have to be a Rule Breaker to earn big returns in the pharmaceutical sector. Pfizer has been a winning pick for Philip Durell and subscribers to his Motley Fool Inside Value stock-picking service. See what the fuss is all about by taking a 30-day risk-free trial today.
Fool by Numbers is designed to give you the raw earnings information in a timely fashion, putting all the numbers you need in one easy-to-read place. But at The Motley Fool, we believe numbers tell only part of the story, so check Fool.com for more of our in-depth discussion of what the numbers mean.
Fool contributor Tim Beyers didn't own stock in any of the companies mentioned in this story at the time of publication. You can find out what's in his portfolio by checking Tim's Fool profile here . The Motley Fool has an ironclad disclosure policy .
